Analysts Perspectives: Novavax Inc (NASDAQ:NVAX)

Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Price targets reflect what the analyst believes a stock will be worth four quarters into the future.

NVAX's revenue has grown at an average annualized rate of about 0.9% during the past five years. This company shares are 40.41% off its target price of $21.82 and the current market capitalization stands at $3.56B.

Novavax, Inc. (NVAX) stock price distance from twenty day simple moving average surged at 26.16% while its distance from fifty day simple moving average raised 3.57% along with -52.85% below distance from two hundred simple moving averages. Over the last three months, the shares of the company have changed -30.13% and performed -19.85% over the last six months. Finally, JPMorgan Chase & Co. increased its position in shares of Novavax by 110.5% in the third quarter. The Average True Range (ATR) is a measure of stock volatility. Hedge funds and other institutional investors own 60.36% of the company's stock.

Recent action on shares of Proteon Therapeutics, Inc. The stock exchanged hands with 7.49 million shares contrast to its average daily volume of 7.95 million shares. The stock appeared $8.49 above its 52-week highs and is up 17.20% for the last five trades.

The SMA or Simple Moving Averages are commonly available for 20 Day, 50 Day and 200 Day Simple Moving Averages. The stock's market cap is $308.03 million.

Previously Novavax Inc (NASDAQ:NVAX) reported $-0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.17 by $0.01.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Novavax Inc (NASDAQ:NVAX) high price target of $12 and with a conservative view have low price target of $0.9. The Return on Equity (ROE) value stands at -787.4%. The business had revenue of $5.68 million during the quarter, compared to the consensus estimate of $6.17 million. Analysts predict that Novavax, Inc. will post ($0.62) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: "Novavax, Inc". The original version of this story can be read at Zacks Investment Research upgraded Novavax from a "sell" rating to a "buy" rating and set a $1.75 target price for the company in a research note on Friday, March 3rd.

Novavax, Inc. (NASDAQ:NVAX) closed at $1.09 gaining 5.83% on a volume of 4.52 million shares.

Some buy side analysts are also providing their Analysis on Novavax, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 6 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. The stock now has an average rating of "Hold" and an average target price of $5.61. The return on invested capital at 0%, which is good, compared to its peers. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.50% of the company's stock. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV).

Latest News